5 March 2024
Hepatitis
18 September 2023
Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective
In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…
READ MORE
19 June 2023
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…
READ MORE
31 May 2023
APASL 2023 Taiwan Congress Report
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MORE
14 March 2023
Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE
14 March 2023
Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE
14 March 2023
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma
This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…
READ MORE
14 March 2023
Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…
READ MORE
13 March 2023
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…
READ MORE
9 December 2022
Liver Disease in Asia Pacific: Insights from Prof Pierce Chow
In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MORE
9 December 2022
Tackling HCV in Punjab: local experts share strategies for success
Punjab is one of Pakistan’s largest provinces and has a particularly high HCV prevalence rate of roughly 9%, compared to 5.4% for Pakistan’s total population. Hear…
READ MORE
9 December 2022
Pakistan’s national HCV elimination programme: insights from Dr Huma Qureshi
In 2019, Pakistan announced a nationwide programme to scale up HCV prevention, testing and treatment. Hear from gastroenterologist Dr Huma Qureshi, a key figure in Pakistan’s…
READ MORE
9 December 2022
Hepatitis C: the patient journey from screening to diagnosis and treatment
An estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV), with a large proportion currently being undiagnosed or diagnosed late.…
READ MORE
9 December 2022
HCV screening in Egypt: key elements of a successful national screening programme
In 2018, the world’s largest HCV screening campaign was initiated in Egypt. Within 7 months following its initiation, 49.5 million people were screened; and 2.2 million…
READ MORE
9 December 2022
HCV elimination in Sindh: insights from Prof Muhammad Sadik Memon and Dr Zaigham Abbas
The province of Sindh has one of the world’s highest rates of HCV infection and bears the second highest disease burden of both HBV and HCV…
READ MORE
9 December 2022
HCV elimination in Pakistan: insights from Dr Zaigham Abbas
Pakistan has one of the world’s highest rates of HCV infection. Learn from Dr Zaigham Abbas, Head of Gastroenterology at Ziauddin University Hospital and President of…
READ MORE
9 December 2022
HCV elimination in Northern Pakistan: Prof Aamir Khan on treating patients in KPK province and the Afghan borderlands
Pakistan has one of the world’s highest rates of HCV infection. It's no surprise that their healthcare systems face mounting pressure from HCV-related conditions. Learn from…
READ MORE
9 December 2022
Future therapies for chronic Hepatitis B and the role of diagnostics
Hepatitis B is an important infectious disease problem in the APAC region. Learn from Prof Henry Chan, director of the Center for Liver Health at Chinese…
READ MORE